Diagnostic value of determining the level of purine metabolism intermediates in pregnant women with chronic hypertension and superimposed preeclampsia

Dinara Omertayeva¹, Olga Ponamaryova², Zhanna Amirbekova¹, Dmitriy Vazenmiller¹, Miras Mugazov³

¹Department of Obstetrics and Gynecology, National Join-stock Company, Karaganda Medical University, Karagandy, Kazakhstan
²Department of Fundamental Medicine, National Join-stock Company, Karaganda Medical University, Karagandy, Kazakhstan
³Department of Surgical Diseases, National Join-stock Company, Karaganda Medical University, Karagandy, Kazakhstan

ARTICLE INFO

Article type: Original Article
Article history:
Received: 5 April 2020
Accepted: 31 August 2020
Published online: 27 October 2020

Keywords:
Purine intermediates
Purine metabolism
Chronic hypertension
Proteinuria
Thrombocytopenia

ABSTRACT

Introduction: Chronic hypertension and related cardiovascular diseases are some of the leading causes of maternal and perinatal morbidity and mortality in the world. Chronic hypertension in pregnant women is associated with many severe outcomes, including preeclampsia, eclampsia, cesarean section, cerebrovascular injury, fetal growth retardation, and premature birth, maternal and also perinatal mortality. In 0.9%–1.5% of pregnant women, it can lead to maternal, intrauterine, and neonatal morbidity and mortality.

Patients and Methods: Around 139 patients were examined, including 110 pregnant women and 29 healthy non-pregnant women of childbearing age (control group). The content of purine metabolism intermediates was determined: guanine, hypoxanthine (HX), adenine, xanthine (X) and uric acid (UA) - in plasma and erythrocytes. We also determined the level of blood platelets, proteinuria in the general analysis of urine in pregnant women with chronic arterial hypertension, severe preeclampsia, and in pregnant women with chronic hypertension with superimposed preeclampsia.

Results: The level of purine catabolism intermediates significantly exceeds in the blood of pregnant women with chronic hypertension and superimposed preeclampsia compared to control group. It was determinate that purine intermediates a significant increase in pregnant women with chronic hypertension with superimposed preeclampsia compared to pregnant women with isolated chronic hypertension, pregnant women with severe preeclampsia. An analysis of correlations showed that the increase in purine intermediates in blood in pregnant women with chronic hypertension and superimposed preeclampsia is associated with an increase in proteinuria and thrombocytopenia. It indicates a diagnosis of preeclampsia to chronic hypertension. It can be an additional diagnostic criterion, along with proteinuria and thrombocytopenia.

Conclusion: Determination of purine intermediates can be used as an additional diagnostic criterion in pregnancy with chronic hypertension.

Implication for health policy/practice/research/medical education:
Determination of purine metabolites will allow timely prevention of preeclampsia complications. Determination of purine metabolites in pregnant women with chronic hypertension with superimposed preeclampsia is a contribution to fundamental research in pregnancy hypertension. It is an innovative approach to the diagnosis of preeclampsia.

Please cite this paper as: Omertayeva D, Ponomaryova O, Amirbekova Z, Vazenmiller D, Mugazov M. Diagnostic value of determining the level of purine metabolism intermediates in pregnant women with chronic hypertension and superimposed preeclampsia. J Nephropathol. 2021;10(s):exx. DOI: 10.34172/jnp.2021.xx.

*Corresponding author: Dinara Omertayeva, Email: omertaevadinara@list.ru
and hypoxanthine are metabolic products of adenine and guanine. Xanthine, which is the end product of purine catabolism (4). The increase in blood pressure and proteinuria, platelet aggregation and consumption are absent unlike increased blood pressure and proteinuria, platelet activation, aggregation and consumption are absent in gestational or chronic hypertension. As in the case of thrombocytopenia, a sudden increase in the level of hepatic enzymes or a sudden development of symptoms characteristic of preeclampsia confirm the addition of preeclampsia, because unlike increased blood pressure and proteinuria, platelet activation, aggregation and consumption are absent in gestational or chronic hypertension. The abrupt onset of thrombocytopenia can be a diagnostically valuable evidence of the addition of preeclampsia, because unlike increased blood pressure and proteinuria, platelet activation, aggregation and consumption are absent in gestational or chronic hypertension. As in the case of thrombocytopenia, a sudden increase in the level of hepatic enzymes or a sudden development of symptoms characteristic of preeclampsia confirm the addition of preeclampsia. Another way to verify of preeclampsia to chronic hypertension is to increase the level of uric acid, which is the end product of purine catabolism (4). The main purine bases are adenine and guanine. Purines exert their effect by activating specific receptors, since purine receptors are widely present in the cells of blood vessels, heart, liver, kidneys and other organs (5). In particular, various types of P2Y receptors are found in a healthy heart and in the development of heart failure (6,7). However, there are many questions about the effect of other intermediates of purine catabolism in the pathogenesis of preeclampsia and chronic arterial hypertension.

Objectives
The aim of the study was to evaluate the diagnostic value of purine metabolism products in plasma and erythrocytes in pregnant women with chronic hypertension with superimposed preeclampsia.

Patients and Methods

Study population
A total of 139 patients were examined, 110 of them were pregnant women hospitalized in the Regional Clinical Hospital, Perinatal Center and 29 patients were healthy non-pregnant women of childbearing age. The criteria for the inclusion of pregnant women in the study was the informed consent of the woman to participate in the study, gestational age 20-42 weeks of gestation, the presence of the studied pregnancy pathology. The exclusion criteria were oncological diseases, HIV infection, tuberculosis, concomitant severe somatic pathology (diabetes mellitus, bronchial asthma, renal, liver failure, all types of collagen vascular diseases and autoimmune diseases), obesity, mental illness and drug addiction.

Pregnant women were divided into three groups and a control group:

- **Group 1;** 32 pregnant women with severe chronic hypertension (a women with history of chronic hypertension, at a systolic blood pressure (SBP) level of ≥160 mm Hg and/or diastolic blood pressure (DBP) ≥110 mm Hg, without proteinuria or thrombocytopenia.
- **Group 2;** 48 pregnant women with severe preeclampsia (a woman with SBP level of ≥160 mm Hg and/or DBP ≥110 mm Hg after 20 gestational weeks and proteinuria 0.3 g/L and more)
- **Group 3;** 30 pregnant women with chronic hypertension with superimposed preeclampsia (a women with history of chronic hypertension, at SBP level of ≥160 mm Hg and/or DBP ≥110 mm Hg with proteinuria or thrombocytopenia).
- **Group 4;** control group - 29 healthy non-pregnant women of childbearing age.

The diagnosis of severe preeclampsia, chronic severe arterial hypertension, and chronic hypertension with superimposed preeclampsia was made on the basis of the...
Ethical issues

The study was performed in agreement with the principles of the Declaration of Helsinki, 1996 version and its later amendments and also Good Clinical Practice standards. Each patient who took part in the study signed the informed consent form. The study design was approved by the Bioethics Committee of the Karaganda Medical University (No. 33 dated January 3, 2018). All patients’ information remained confidential.

Statistical analysis

Statistical analysis of the data was carried out using the software package SPSS version 22.0, taking into account the computational methods recommended for biology and medicine. The analysis of the obtained data included the calculation of the median, upper and lower quartiles. Given the abnormal distribution of the studied parameters, the reliability of the observed differences was determined by the nonparametric method of variance analysis using the Kruskal-Wallis test, with further pairwise determination of the significant differences between the groups using the Mann-Whitney test (Table 1). To identify the relationships between the studied values and establish the strength of these bonds, the Spearman’s pair correlation coefficients (r) were calculated (Table 3).

Results

The results of the study of the content of purine metabolism intermediates in erythrocytes and plasma of pregnant women with various types of hypertension are presented in Tables 1 and 2, respectively. When determining the content of purine metabolism products in erythrocytes in pregnant women with all types of hypertension, statistically significant differences were found with respect to control, to a greater extent in group 3 (P = 0.0001). The content of guanine, HX, adenine, UA in the blood erythrocytes of pregnant women with chronic hypertension with superimposed preeclampsia is significantly higher than in pregnant women with chronic arterial hypertension and severe preeclampsia, however, the level of xanthine does not differ among all groups of pregnant women with hypertension.

In blood plasma, the content of purine metabolism products statistically significantly differs relative to the

Table 1. The content of metabolites of purine metabolism in red blood cells in pregnant women with various types of hypertension

<table>
<thead>
<tr>
<th>Indicator</th>
<th>1-Severe chronic hypertension (n=32) (Q25, Q75)</th>
<th>2-Severe preeclampsia (n=47) (Q25, Q75)</th>
<th>3-Chronic hypertension with superimposed preeclampsia (n=30) (Q25, Q75)</th>
<th>4-Control group (n=30) (Q25, Q75)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guanine (Median)</td>
<td>276* (263; 298)</td>
<td>422* (384; 459)</td>
<td>544*# (547; 1139)</td>
<td>171 (173; 221)</td>
</tr>
<tr>
<td>Hypoxanthine (Median)</td>
<td>459*# (398; 485)</td>
<td>381*# (360; 469)</td>
<td>746* (748; 1284)</td>
<td>162 (156; 207)</td>
</tr>
<tr>
<td>Adenine (Median)</td>
<td>493* (421; 525)</td>
<td>357# (339; 449)</td>
<td>683*# (684; 1237)</td>
<td>451 (349; 497)</td>
</tr>
<tr>
<td>Xanthine (Median)</td>
<td>224 (209; 271)</td>
<td>207* (195; 250)</td>
<td>284* (327; 984)</td>
<td>194 (174; 217)</td>
</tr>
<tr>
<td>Urine acid (Median)</td>
<td>104*# (96; 139)</td>
<td>118* (101; 140)</td>
<td>168* (179; 289)</td>
<td>75 (73; 81)</td>
</tr>
<tr>
<td>X/HX</td>
<td>0.48</td>
<td>0.54</td>
<td>0.38</td>
<td>1.19</td>
</tr>
<tr>
<td>UA/HX</td>
<td>0.23</td>
<td>0.31</td>
<td>0.23</td>
<td>0.46</td>
</tr>
<tr>
<td>UA/X</td>
<td>0.46</td>
<td>0.57</td>
<td>0.59</td>
<td>0.39</td>
</tr>
</tbody>
</table>

* Statistically significantly differs relative to control (p ≤ 0.013).
# Statistically significant differences between group 3 and group 1, 2 according to the Mann-Whitney criterion (p ≤ 0.013).
The content of metabolites of purine metabolism in plasma in pregnant women with various types of hypertension

<table>
<thead>
<tr>
<th>Indicator</th>
<th>1-Severe chronic hypertension (n=32), (Q25, Q75)</th>
<th>2-Severe preeclampsia (n=47), (Q25, Q75)</th>
<th>3-Chronic hypertension with superimposed preeclampsia (n=30), (Q25, Q75)</th>
<th>4-Control group (n=30), (Q25, Q75)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guanine (Median)</td>
<td>222* (199; 341)</td>
<td>284*# (259; 348)</td>
<td>440*# (398; 4711)</td>
<td>159 (156; 178)</td>
</tr>
<tr>
<td>Hypoxanthine (Median)</td>
<td>209* (201; 300)</td>
<td>261*# (250; 335)</td>
<td>559*# (548; 653)</td>
<td>166 (158; 235)</td>
</tr>
<tr>
<td>Adenine (Median)</td>
<td>208* (175; 256)</td>
<td>218*# (207; 286)</td>
<td>384*# (350; 462)</td>
<td>135 (135; 153)</td>
</tr>
<tr>
<td>Xanthine (Median)</td>
<td>206* (194; 263)</td>
<td>207*# (203; 252)</td>
<td>299*# (262; 396)</td>
<td>139 (136; 164)</td>
</tr>
<tr>
<td>Urine acid (Median)</td>
<td>219*# (184; 240)</td>
<td>214*# (187; 239)</td>
<td>506*# (449; 522)</td>
<td>114 (113; 161)</td>
</tr>
<tr>
<td>X/HX</td>
<td>0.99</td>
<td>0.79</td>
<td>0.40</td>
<td>0.84</td>
</tr>
<tr>
<td>UA/HX</td>
<td>1.05</td>
<td>0.82</td>
<td>0.71</td>
<td>0.69</td>
</tr>
<tr>
<td>UA/X</td>
<td>1.06</td>
<td>1.03</td>
<td>1.77</td>
<td>0.82</td>
</tr>
</tbody>
</table>

* Statistically significant differences with control according to the Kruskal-Wallis test (≤0.013).
# Statistically significant differences between group 3 and group 1, 2 according to the Mann-Whitney criterion (≤0.013).

Control. The mostly high level of purine bases and purine intermediates was found in the third group of pregnant women compared with the control, the first and second groups of pregnant women. It was found a trend of increasing of purine metabolism intermediates in the second group relative to the first group.

The calculation of the indices characterizing the activity of xanthine oxidase in red blood cells showed the following findings: in pregnant women with all types of hypertension, there was a tendency toward a decrease in X/HX and UA/HX in erythrocytes, mostly in the 3rd group of pregnant women, relative to the control group, which indicates a certain decrease in xanthine oxidase activity, however, UA/X in red blood cells of the second and third groups pregnant is more elevated. In plasma, the coefficients X/HX, UA/HX, UA/X in all groups of pregnant women are lower than in the control group, which indicates a decrease in xanthine oxidase activity in blood plasma.

Table 3 presents the correlation analysis. Thus, in the third group of pregnant women with chronic arterial hypertension with superimposed preeclampsia, a statistically significant negative correlation between the level of proteinuria and hypoxanthine was determined. A statistically significant positive correlation was also found between proteinuria and xanthine in blood plasma, uric acid in erythrocytes, and blood platelets. At the same time, a statistically significant negative correlation was determined between blood platelets and guanine, plasma hypoxanthine, a positive correlation with proteinuria.

In group 1 of pregnant women with severe chronic hypertension, when determining the correlation between proteinuria and the level of purine intermediates, we found statistically significant positive correlations between the level of proteinuria and xanthine and also with plasma uric acid.

A positive significant correlation was found between platelets and uric acid in pregnant women in the second group with severe preeclampsia.

Discussion

An analysis of the results allowed us to draw the following conclusions. In pregnant women with chronic hypertension with superimposed preeclampsia, the level of purine catabolism intermediates significantly exceeds the control values, as well as the comparison groups both in red blood cells and in blood plasma. The main trends in the indices characterizing the activity of xanthine oxidase demonstrate a change in its activity in the blood plasma towards an increase, while at the same time its decrease in the blood erythrocytes of pregnant women with all types of hypertension relative to control. This is probably due to the increased release of purines from cells under the conditions of increasing hypoxia, oxidative stress (hypoxanthine is considered as a biochemical marker of hypoxia) and inhibition of the antioxidant defense of the body under conditions of oxidative stress. Additionally, a tendency to an increase in purine metabolites can also be associated with a violation of the reverse transport of purine nucleotides and intermediates of their catabolism into cells, which is caused by impaired capture by their specific receptors on cell membranes. At the same time, xanthine is able to provoke vasoconstriction, which is characteristic of hypertensive conditions. Uric acid and xanthine are inducers of endothelial vessel damage, which contributes to the progression of preeclampsia, further damage to the glomeruli of the kidneys and aggravation during preeclampsia.

An analysis of correlations showed that the increase in purine intermediates in blood plasma in pregnant women with chronic hypertension with superimposed preeclampsia is associated with an increase in proteinuria,
Table 3. Results of pair correlation analysis (Spearman r-coefficients) of purine metabolism and protein in OAM, blood platelet count in pregnant women of group 3 (pregnant women with chronic hypertension with superimposed preeclampsia)

<table>
<thead>
<tr>
<th></th>
<th>Guanine of plasma 3</th>
<th>Hypoxanthine of plasma 3</th>
<th>Adenine of plasma 3</th>
<th>Xanthine of plasma 3</th>
<th>Urine acid of plasma 3</th>
<th>Proteinuria 3</th>
<th>Platelets 3</th>
<th>Guanine of erythrocytes 3</th>
<th>Hypoxanthine of erythrocytes 3</th>
<th>Adenine of erythrocytes 3</th>
<th>Xanthine of erythrocytes 3</th>
<th>Urine acid of erythrocytes 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proteinuria 3</td>
<td>-0.088</td>
<td>-0.6**</td>
<td>-0.1</td>
<td>0.5**</td>
<td>-0.2</td>
<td>-</td>
<td>0.5**</td>
<td>0.3</td>
<td>0.2</td>
<td>0.04</td>
<td>0.2</td>
<td>0.4*</td>
</tr>
<tr>
<td>Platelets 3</td>
<td>-0.4*</td>
<td>-0.6**</td>
<td>-0.05</td>
<td>0.2</td>
<td>-0.18</td>
<td>0.5**</td>
<td>-</td>
<td>0.4*</td>
<td>0.2</td>
<td>0.1</td>
<td>0.3</td>
<td>0.2</td>
</tr>
</tbody>
</table>

** The correlation is significant at the level of 0.01 (two-way).
* The correlation is significant at the level of 0.05 (two-way).

Table 4. Results of pair correlation analysis (Spearman's r-coefficients) of purine metabolism and protein in OAM, blood platelet count in pregnant women of group 1 (pregnant women with severe chronic hypertension)

<table>
<thead>
<tr>
<th></th>
<th>Guanine of plasma 1</th>
<th>Hypoxanthine of plasma 1</th>
<th>Adenine of plasma 1</th>
<th>Xanthine of plasma 1</th>
<th>Urine acid of plasma 1</th>
<th>Proteinuria 1</th>
<th>Platelets 1</th>
<th>Guanine of erythrocytes 1</th>
<th>Hypoxanthine of erythrocytes 1</th>
<th>Adenine of erythrocytes 1</th>
<th>Xanthine of erythrocytes 1</th>
<th>Urine acid of erythrocytes 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proteinuria 1</td>
<td>0.2</td>
<td>0.3</td>
<td>0.2</td>
<td>0.4*</td>
<td>0.5**</td>
<td>-</td>
<td>0.7</td>
<td>-0.02</td>
<td>0.18</td>
<td>0.16</td>
<td>0.24</td>
<td>0.18</td>
</tr>
<tr>
<td>Platelets 1</td>
<td>-0.3</td>
<td>-0.2</td>
<td>-0.2</td>
<td>-0.2</td>
<td>-0.2</td>
<td>0.3</td>
<td>-</td>
<td>0.1</td>
<td>0.1</td>
<td>0.08</td>
<td>0.14</td>
<td>0.13</td>
</tr>
</tbody>
</table>

** The correlation is significant at the level of 0.01 (two-way).
* The correlation is significant at the level of 0.05 (two-way).

Table 5. Results of pair correlation analysis (Spearman's r-coefficients) of purine metabolism and protein indicators in OAM, blood platelet count in pregnant women of group 2 (pregnant women with severe preeclampsia)

<table>
<thead>
<tr>
<th></th>
<th>Guanine of plasma 2</th>
<th>Hypoxanthine of plasma 2</th>
<th>Adenine of plasma 2</th>
<th>Xanthine of plasma 2</th>
<th>Urine acid of plasma 2</th>
<th>Proteinuria 2</th>
<th>Platelets 2</th>
<th>Guanine of erythrocytes 2</th>
<th>Hypoxanthine of erythrocytes 2</th>
<th>Adenine of erythrocytes 2</th>
<th>Xanthine of erythrocytes 2</th>
<th>Urine acid of erythrocytes 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proteinuria 2</td>
<td>0.09</td>
<td>0.08</td>
<td>0.2</td>
<td>0.02</td>
<td>-0.06</td>
<td>-</td>
<td>0.06</td>
<td>-0.06</td>
<td>-0.03</td>
<td>-0.05</td>
<td>0.03</td>
<td>0.09</td>
</tr>
<tr>
<td>Platelets 2</td>
<td>0.14</td>
<td>0.16</td>
<td>0.16</td>
<td>0.24</td>
<td>0.33*</td>
<td>0.06</td>
<td>0.05</td>
<td>0.05</td>
<td>0.16</td>
<td>0.19</td>
<td>0.09</td>
<td></td>
</tr>
</tbody>
</table>

** The correlation is significant at the level of 0.01 (two-way).
* The correlation is significant at the level of 0.05 (two-way).
thrombocytopenia and indicates the addition of preeclampsia in pregnant women with chronic hypertension and can be considered as an additional diagnostic criterion, along with proteinuria and thrombocytopenia. In cases of difficulty in diagnosing preeclampsia in pregnant women with chronic hypertension, the determination of purine metabolism intermediates contributes to the correct diagnosis and, mostly importantly, timely treatment. The only etiological method of treating chronic hypertension with superimposed preeclampsia is timely delivery. In cases where the diagnosis is not accurately verified, further prolongation of pregnancy can lead to complications of preeclampsia (eclampsia, HELLP syndrome, placental abruption).

**Conclusion**
An increase in the concentration of purine metabolism catabolites is a prognostically unfavorable factor, since purine bases play an important role in the progression of systemic endotheliosis characteristic of preeclampsia. Based on the results obtained, it is possible to propose the determination of the level of purine intermediates in blood plasma as an additional diagnostic tool confirming the layering of preeclampsia in pregnant women with chronic hypertension.

**Limitations of the study**
It had some limitations including lack of follow-up of patients, which would demonstrate long-term renal outcomes, but was beyond the objectives of the present study due to the cross-sectional nature of the study.

**Acknowledgments**
We would like to thank the laboratory of fundamental sciences of Karaganda Medical University.

**Authors' contribution**
DO, OP; ZA, DV and MM conducted the research. DO participated in all steps of creation of article. DV, ZA and MM collected material. OP checked statistical calculations. DO revised and prepared the final manuscript. All authors participated in all steps of creation of article. DV, ZA and MM conducted the research. DO, OP, ZA, DV and MM participated in all steps of creation of article.

**Funding/Support**
This study is being conducted as part of PhD studies by Dinara Omertayeva and is supported by Karaganda Medical University.

**References**

**Copyright** © 2021 The Author(s); Published by Society of Diabetic Nephropathy Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.